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Abstract
Background: Globally, most strokes occur in low- and middle-income countries, such as India, with many affected
people having no or limited access to rehabilitation services. Western models of stroke rehabilitation are often
unaffordable in many populations but evidence from systematic reviews of stroke unit care and early supported
discharge rehabilitation trials suggest that some components might form the basis of affordable interventions in
low-resource settings. We describe the background, history and design of the ATTEND trial, a complex intervention
centred on family-led stroke rehabilitation in India.
Methods/design: The ATTEND trial aims to test the hypothesis that a family-led caregiver-delivered home-based
rehabilitation intervention, designed for the Indian context, will reduce the composite poor outcome of death or
dependency at 6 months after stroke, in a multicentre, individually randomized controlled trial with blinded
outcome assessment, involving 1200 patients across 14 hospital sites in India.
Discussion: The ATTEND trial is testing the effectiveness of a low-cost rehabilitation intervention that could be
widely generalizable to other low- and middle-income countries.
Trial registration: Clinical Trials Registry-India CTRI/2013/04/003557. Australian New Zealand Clinical Trials Registry
ACTRN12613000078752. Universal Trial Number U1111-1138-6707.
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Background
Stroke causes 6 million deaths each year among 17 mil-
lion affected people, with the greatest burden experi-
enced in populations of low- and middle-income
countries [1]. In these countries, the burden of stroke is
increasing, owing to lifestyle changes and rapid ageing of
populations. Furthermore, stroke tends to affect people
at relatively younger ages where there is poor control of
established risk factors, in particular high blood pressure
[2], with significant social and financial consequences
for families, owing to limited financial protection from
the costs of care and minimal social safety nets [3].
Stroke usually affects at least two people in a family, the
patient and at least one family caregiver, with epidemic
proportions of premature loss of productive lives in
developing countries, such as India [4–6].
Like many developing countries, India is experiencing
an epidemiologic transition, in which the burdens of
infectious disease, maternal and child health problems
are decreasing, while the burden of non-communicable
chronic diseases, such as stroke and injury, is increasing
[7]. In India, based upon an annual incidence of stroke
of 135 to 145 per 100,000, and early case fatality of
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between 27 % and 41 % [7–10], it has been estimated
that 1.5 million people experience stroke each year,
and a further 500,000 people live with stroke-related
disability. The long-term consequences of stroke on
families in India, particularly in rural areas, are likely
to be significant.
The most important treatment for patients with stroke
is well-organized specialist care [11], which allows rapid
and well-coordinated assessment and diagnosis [12, 13],
early recognition and management of complications,
early rehabilitation, education, and appropriate long-
term support and secondary preventative therapy. Stroke
unit care has greater public health impact than treat-
ment with thrombolysis (alteplase) alone, even with the
most optimal thrombolysis rates [11], because thromb-
olysis rates are rarely greater than 20 % (with a 5–10 %
absolute benefit), yet stroke unit care is applicable to
all (with a 5 % absolute benefit). Organized stroke
care should be a public health priority in low- and
middle-income countries, to ameliorate the increasing
burden of stroke.
Although appropriate stroke unit care and rehabilita-
tion may meet important clinical, physical and psycho-
social needs during the early post-stroke phase, the
needs of patients and families in the long term cannot
solely be addressed in hospital [14, 15]. Advocates for
early supported discharge and home-based stroke re-
habilitation, which is based upon a coordinated stroke
unit model of care, argue that it offers several advan-
tages: satisfying patient choice; reducing risks (and costs)
associated with inpatient care through reductions in
length of hospital stay; a better rehabilitation setting, as
the home setting is more focused towards realistic goals,
social inclusion and a supportive environment; and lead-
ing to savings in direct and indirect costs [16, 17]. Early
supported discharge provides a continuous process of
rehabilitation that spans the in-hospital period and the
weeks of resettlement and readjustment at home. A
meta-analysis of 11 trials (mainly conducted in devel-
oped countries, where fully funded community rehabili-
tation teams are available) shows that early supported
discharge services significantly reduced the odds of death
or dependency by 21 % (odds ratio 0.79; 95 % confidence
interval 0.64–0.97), without major adverse effects, either
on patients or caregivers [17].
Although acute stroke units are increasing as re-
sources improve in India, they meet the needs of only a
tiny fraction of the country’s vast population, and the
majority of Indians do not have access to rehabilitation
services, either in hospital or following discharge. The
development of effective low-cost community rehabili-
tation services for emerging major chronic diseases,
such as stroke in India, has the potential for significant
public health impact. Such interventions, if shown to
be effective and affordable, could be widely scaled up or
generalizable. Indeed, the research question of how to
create sustainable and multiprofessional rehabilitation
systems in low- and middle-income countries, includ-
ing the provision of services to the rural population,
was considered the second most important research
priority (after equality of healthcare access) for disabled
people in a recent Lancet expert panel [18]. Currently,
most Indian stroke units are situated in the private
sector [19, 20]. Clear evidence that low-cost interven-
tions are cost-effective in India would facilitate their
expansion within the public hospital system, where
rehabilitation has some important features that differ
from those in high-income countries: therapy is driven
largely by physiotherapists, with limited input from
other health professionals, such as occupational thera-
pists; it is often poorly coordinated; and most people
receive care within a large family unit (‘a joint family’,
often called an extended family) after discharge [21].
A modified version of the Western model of early
supported discharge, together with a development of the
Indian-suggested solution based on rehabilitation deliv-
ered by a trained family caregiver, appears to be the
most promising hybrid model of stroke care that could
be widely implemented, if shown to be successful. Similar
models have been shown to be cost-effective in the UK
[22, 23]. To develop appropriate health policy, though,
effectiveness and cost-effectiveness of any new model of
care including rehabilitation needs rigorous evaluation in
the relevant setting.
Methods
The ATTEND study is a multicentre, prospective, indi-
vidually randomized, blinded outcome assessed, controlled
trial (prospective, randomized, open, blinded, endpoint
design) of early supported discharge with a trained
family-led caregiver.
The intervention is a stroke rehabilitation package of
care that starts in hospital and continues at home,
compared with usual care, in at least 1200 patients with
mild to moderate disability recruited from 14 hospital
sites across India.
The inclusion criteria are:
 Adults (≥18 years);
 Recent (<1 month) acute ischaemic, haemorrhagic
or undifferentiated stroke;
 Residual disability (requiring help from another
person for everyday activities);
 Expected to survive to discharge from hospital,
with a reasonable expectation of 6 month survival
(i.e. not palliative, no evidence of widespread
cancer etc.);
 Able (or by proxy) to provide informed consent.
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Exclusion criteria are:
 Unable to identify a suitable family-nominated care-
giver for training and subsequent delivery of care;
 Unwilling or unable to adhere to follow-up.
Randomization
Eligible patients are identified by the trial stroke coord-
inator (usually a physiotherapist) and medical coordin-
ator. A patient information sheet (Additional file 1) is
shared with the patient and nominated caregiver, and
outlines the study objectives and risks and benefits to
the patient or caregiver. Informed consent from each
participant and his or her caregiver is obtained based on
the International Conference on Harmonisation Good
Clinical Practices guidelines (ICH/GCP) and ethical
guidelines for biomedical research on human partici-
pants published by the Indian Council of Medical
Research, New Delhi (Fig. 1). If the caregiver changes by
the time of the 3- or 6-month follow-up periods, the
new caregiver will be asked to provide consent for the
caregiver aspects of follow-up after reading the patient
information sheet. Stroke patients often do not have the
capacity to consent, owing to the acute effects of stroke.
Capacity for informed consent is assessed by the medic-
ally qualified principal investigator at each site. The
ethics committee have approved ATTEND to obtain
consent from a legally acceptable representative in such
cases. Once consented, patients are randomized by the
trial stroke coordinator to the intervention or control
arm in a 1:1 ratio within 7 days of hospital admission,
using a secure, central, password-protected, web-based
system, stratified by centre and stroke severity.
Intervention arm
Patients allocated to the intervention arm have their
family-nominated caregiver trained by a specially trained
trial stroke coordinator health professional (e.g., nurse,
therapist) using a trial-specific structured assessment
(cognition, language, function and mobility) and recom-
mended rehabilitation package. The rehabilitation package
includes a structured checklist and culturally appropriate
manual (adapted to local Indian contemporaneous stroke
practice) covering key activities relevant to daily living
(e.g., positioning, transfers, mobilization, feeding, dressing,
activity and motor practice, and monitoring of mood).
Detailed instructions for selected training exercises are
used from http://www.physiotherapyexercises.com. Train-
ing begins in hospital immediately after randomization for
those allocated to the intervention, with a goal of
approximately 60 min training per day for about 3 days,
with the intention of accelerating the patient’s hospital
discharge, when it is safe to do so, in addition to usual
hospital care. The trial stroke coordinator visits the
patient and caregiver’s home, if they are allocated to the
intervention arm, on up to six occasions over the next 2
months, to provide guidance and to monitor progress
after discharge, and is available by telephone for further
support and guidance as the patient progresses.
A detailed written intervention guide, adapted from
previous work [24], instructs all trial stroke coordinators
in delivering the structured intervention in a standardized
manner; this is reinforced at training sessions during the
annual collaborators’ meetings.
The intervention components are:
 Information on stroke recovery trajectory, risk,
identification and management of low mood,
importance of repeated practice of specific activities.
 Positioning, transfers and mobility.
 Discharge planning.
 Joint goal setting with patient, nominated family
caregiver and therapist (reviewed with coordinator
as patient progresses and new goals set).
 Task-orientated training (particularly walking, upper
limb and self-care tasks) with personalized copy of
culturally appropriate manual.
The detailed intervention guide and manual are kept
confidential and will only be published after the last
patient follow-up has been completed, to avoid con-
tamination of the control patients during the conduct
of the trial.
Control arm
These patients will receive usual hospital care in terms
of access to rehabilitation, timeliness of discharge and
follow-up, without any explicit provision of accelerated
discharge or caregiver training.
Outcome measurement
The primary outcome measure is the effect of treatment
allocation on death or dependency (a score of 0–2 on
the modified Rankin scale [25]) at 6 months after
randomization [26]. Patients will be seen after 3 and 6
months by an independent blinded assessor who will
collect the primary and secondary outcome data.
Secondary outcome measures are:
 Effect of treatment on shift in disability, as measured
by the modified Rankin scale, and analyzed with
shift (ordinal) analysis;
 Answers to the simple validated recovery (Have you
made a complete recovery from your stroke?) and
dependency (Do you need help from another person
for everyday activities?) questions [27];
 Hospital length of stay;
 Place of residence;
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Fig. 1 Study flow chart. ADL, activities of daily living; EQ-5D-3L, EuroQol 5-Dimensional, 3 Levels; NIHSS, National Institutes of Health Stroke Scale;
WHOQOL-BREF, World Health Organization Quality of Life (Brief)
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 Scores on the Barthel Index [26];
 Score on the Caregiver Burden Scale [28];
 Health-related quality of life (World Health
Organization Quality of Life Assessment and
EuroQol 5-Dimensional scores) [29, 30];
 Patient and caregiver mood (Hospital Anxiety and
Depression Scale) [31];
 Extended activities of daily living (Nottingham
Extended Activities of Daily Living Scale) [32];
 Health care resource use (visits to health professionals,
hospitalization, and medication use) and direct costs
for the patient (e.g. payment to the caregiver to act as
carer for this patient, total direct costs of healthcare
paid by the family since time of stroke);
 Indirect costs (e.g. family member giving up paid
employment to act as caregiver) of the family;
 Direct medical costs (e.g. total expenditure during
hospital admission, including first place where
patient was taken, general or private admission,
length of hospital stay, admission charges,
investigation charges and drug treatment);
 Non-medical direct costs (e.g. travelling costs).
Clinic or telephone follow-up will be offered if home
visits are not possible.
Data are collected on paper forms with an English
translation on one side and the appropriate local Indian
language on the other side. Each patient is identified by
a unique identifier with only local sites holding the
master log of names. The trial database is held and
maintained by The George Institute for Global Health,
with access for analysis determined by the steering
committee. Future access to participant level data and
statistical code will depend on additional funding to
safeguard and prepare the data and is contingent upon
compliance with data management guidelines in India
and Australia.
Adverse events
Given that patients with stroke are expected to experience
frequent adverse events, we defined our ‘expected’ events
a priori. These are listed in a checklist at each follow-up.
Any other adverse event is also recorded. Our expected
serious events are: (1) deaths categorized as vascular
(stroke, myocardial infarction, other vascular), infection,
fracture, other and (2) Hospitalizations (stroke, myocardial
infarction, other vascular, infection, fracture, other).
Risks to internal validity
The main risks to the internal validity of the trial are
‘contamination’ between treatment groups, threats to the
fidelity of the intervention and unblinding. To prevent
‘contamination’ between intervention and control pa-
tients in the ward during the hospital stay, we advise
that the stroke coordinators delivering the intervention
interview patients and carers in a private consulting or
treatment room or use curtains around the patient’s bed.
The time spent by the routine ward physiotherapist with
control and intervention patients is monitored and
recorded, to check that there is no systematic bias in
routine physiotherapy. To help prevent control patients
from viewing the trial manual, the manuals are given to
intervention patients at the time of the first home visit
and a general stroke booklet (placebo) is given to both
groups. The topic of ‘contamination’ forms part of the
regular training at site initiation, site visits and annual
collaborators’ meetings.
Fidelity of the trial intervention is monitored during site
initiation and subsequent site training visits by the clinical
coordination team and a consultant physiotherapist
contracted to help with training. Logs of all intervention
activities are collected and analyzed to summarize the
duration of each intervention and the main activities
within the intervention. In addition, we will document
whether the trial participants were assessed or treated by
the usual routine care physiotherapists, and measure
the total time spent per patient, to ensure that both
intervention and control patients have the same back-
ground rehabilitation care.
Blinding is maintained by employing a dedicated
blinded outcome assessor for each site. It is a require-
ment that the blinded outcome assessor not share the
same office as the stroke coordinator and has separate
computer and scanning equipment. The detailed written
intervention guide has been kept confidential from the site
principal investigators and blinded outcome assessors at
each site. At the annual collaborators’ meetings, there are
separate training sessions for the stroke coordinators and
blinded outcome assessors, to maintain confidentiality of
the intervention details. Patients are asked not to disclose
details of home visits to the blinded outcome assessor, and
intervention patients are asked to hide the trial manual
when the blinded outcome assessors visit. The trial inter-
vention is stopped one month before the first follow-up at
3 months to help reduce unblinding. Any inadvertent
unblinding is recorded by the blinded assessor. Exam-
ples of unblinding are discussed at the plenary sessions
at the collaborators’ meetings to share experiences, and
to implement strategies to prevent future occurrences.
Sample size and statistical consideration
In the meta-analysis of early supported discharge trials,
the proportion of people dead or dependent at the end
of follow-up was 50 % and the likely beneficial effect of
early supported discharge treatment was an odds reduc-
tion of 21 % (95 % confidence interval 3–26 %). There-
fore, the proposed minimum sample size of 1200 (600
per group) provides at least 90 % power (two-tailed α,
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0.05) to detect plausible modest 10.5 % reductions in
death or dependency in the intervention group with
inflation by 20 % to account for patients dropping out of
the trial. Ideally, a higher recruitment will allow a greater
precision for treatment estimates, and could permit
more detailed subgroup analysis; thus, when 1200 patients
have been recruited, and if funding and time permits, the
data and safety monitoring committee will advise on
whether it is safe to continue recruitment. Experience
during 2014 and early 2015 has allowed prediction that
the trial will complete recruitment in early 2016, based on
current strategies.
The intention to treat principle will be applied in all
analysis. The primary endpoint measure is the propor-
tion of those dead or dependent (modified Rankin scale
score 0–2) at 6 months. This will be analyzed using an
unadjusted logistic regression model. Binary secondary
outcomes will be analyzed similarly, using analysis of
variance (t tests) for continuous variables. For the shift
analysis of modified Rankin scale using all seven categor-
ies (including 6 for death), ordinal logistic regression will
be used, after verifying the proportional odds assump-
tion. A statistical analysis plan will be completed prior
to analysis and unblinding of the trial data.
Ethics
Ethical approval has been obtained from Research Integ-
rity, the Human Research Ethics Committee at the
University of Sydney and at each local site (Table 1).
Protocol amendments will be first approved by the
University of Sydney ethics committee and then by local
ethics committees before implementation. The current
approved protocol is version 1.3, dated 9 December 2013.
Data collection and study management
Data will be collected for all patients randomized in
the trial. Baseline data will be collected by the stroke
coordinator and the follow-up data by the blinded out-
come assessor on paper forms with appropriate local
translation and are scanned and directly sent to the
data management team for entry into the electronic
database. The investigators and institution will allow
monitors to verify the data collected on case report
forms with respect to all pertinent medical records,
according to ICH/GCP guidelines [33].
A data and safety monitoring committee, composed of
five experts in the fields of stroke medicine, rehabilitation,
statistics and clinical trials, with appropriate Indian repre-
sentation, is monitoring the study, guided by a written
charter with appropriate stopping rules.
The trial is governed by a steering committee formed
by the applicants of the National Health and Medical
Research Council (NHMRC) grant, and supplemented
as agreed by the committee. The steering committee is
co-chaired by Richard Lindley and GV Murthy. Other
members include Jeyaraj Pandian, Pallab Maulik, Peter
Langhorne, Lisa Harvey, Maree Hackett, Marion Walker,
Anne Forster, BR Shamanna, Craig Anderson and Stephen
Table 1 Trial sites
Collaborator Centre City Name of ethics committee
Dr Jeyaraj D Pandian Christian Medical College and Hospital Ludhiana, Punjab Institutional Ethics Committee
Dr MV Padma All India Institute for Medical
Sciences and Technology
New Delhi Institute Ethics Committee
Dr PN Sylaja Sree Chitra Tirunal Institute for
Medical Sciences and Technology
Trivandrum, Kerala Institutional Ethics Committee
Dr P Vijaya Lalitha Super Specialty Hospital Guntur, Andhra Pradesh Lalitha Super Specialities Hospital
Ethics Committee
Dr Sanjith Aaron Christian Medical College Vellore, Tamil Nadu Office of Research Institutional
Review Board
Dr Jayanta Roy Apollo Gleneagles Kolkata Institutional Ethics Committee
Dr Lydia John Baptist Christian Hospital Tezpur, Assam Research Ethics Committee
Dr Subhash Kaul Nizam Institute for Medical Sciences Hyderabad Nizam’s Institute of Medical Sciences
Institutional Ethics Committee
Dr Dheeraj Khurana Postgraduate Institute for Medical
Sciences and Research
Chandigarh Institute Ethics Committee
Dr NC Borah Guwahati Neurological Research
Centre Hospitals
Assam Institute of Neurological Sciences Trust Ethics Committee
Dr DS Halprashanth Global Hospitals Chennai Institutional Ethics Committee
Dr B Lokesh BGS Global Hospital Bangalore Institutional Ethics Committee
Dr Vivek Nambiar Amrita Institute of Medical Sciences Kochi Institutional Ethics Committee
Dr Sachin Sureshbabu St Stephen’s Hospital New Delhi Ethics Committee of St. Stephen’s Hospital
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Jan. The steering committee is responsible for all major
decisions regarding the running of the trial, the appoint-
ment of trial staff and financial reconciliation for the
NHMRC funding.
The day-to-day management of the trial is undertaken
by a management committee comprised of co-principal
investigators Professors Pandian and Lindley, together
with Mr Mohammed Alim, the trial senior project
manager (based at The George Institute, India), the trial
clinical coordinator (based at the Christian Medical
College Ludhiana), and representatives from the Indian
Institute of Public Health, Hyderabad, together with
appropriate trial administrative staff. These meetings are
conducted weekly by teleconference. Trial monitoring is
performed according to the monitoring plan and as per
ICH/GCP, by the monitors from Indian Institute of
Public Health.
The main results of the trial will be published in the
name of the ‘ATTEND Collaborative Group’ with all
contributions named in the primary trial manuscript.
According to new NHMRC policy, this primary publica-
tion must be free to access. All publications must be
approved by the steering committee with appropriate
authorship determined by the steering committee and
journal regulations. The NHMRC funding will be ac-
knowledged in all publications.
Discussion
The beneficial effects of early supported hospital discharge
and home-based rehabilitation on a patient’s recovery
from stroke are probably due to improved focusing of
therapy around functioning and activities that are most
relevant and familiar within the home environment with
family support. Yet, as most of this research has been
undertaken in urban settings of high-income countries,
the impact in low- and middle-income countries is
unclear. Moreover, uncertainty over the essential staffing
and organizational requirements of such services (i.e. a
complex intervention and organizational transfer) has
hampered their wider implementation and development
in different settings, even in the UK [34].
ATTEND is testing the effectiveness of a low-cost
rehabilitation intervention that could be widely
generalizable to other low- and middle-income coun-
tries. If the trial provides evidence of safety, efficacy
and cost-effectiveness, it is likely that adaptations of
the intervention could then be considered to augment
routine care in high-income countries, with culturally
appropriate adaptations to other low-income, marginalized
or disadvantaged populations.
The ATTEND intervention was developed during
2010–2012 based on emerging new Indian stroke services,
modified by accumulating evidence from the stroke unit
and early supported discharge trials, as advised by an
expert panel of stroke researchers and trial organizers.
The intervention was a pragmatic culturally adapted pack-
age piloted in Ludhiana, Punjab, India [35] and was
further modified based on this experience. After the main
trial was funded, the clinical coordination team developed
the final intervention guide with further advice from the
steering committee, and a trial manual for the intervention
patients was produced.
Careful thought was given to the time and cost im-
plications for the interventions, while keeping in mind
the number and quality of interventions included in
the package; the stroke coordinator is trained to deliver a
tailor-made package for patient-specific functional needs.
The efficacy and safety of health interventions are
best evaluated in randomized controlled trials and our
prospective, randomized, open, blinded, endpoint study
design helps ensure avoidance of bias in the follow-up of
patients, a recurrent problem in previous rehabilitation
trials. Extensive measures were taken to ensure that
assessment was blinded in ATTEND, e.g., keeping the
details of the intervention confidential to the stroke
coordinators, ensuring separate training of the blinded
outcome assessors, and employing dedicated research staff
for the blinded assessment.
India launched its National Programme for Preven-
tion and Control of Diabetes, Cardiovascular Diseases
and Stroke in January 2008. The programme aims to
strengthen infrastructure at all levels of care at the
community level with the help of caregivers, who are
important in the delivery of this programme, and are
thus clearly aligned with a family-led rehabilitation
model [36].
If ATTEND does not show efficacy or results in an
unexpected hazard, data from the trial will inform the
reasons why and what modifications could be made
while balancing the additional costs against the infra-
structure and human resource needs.
Trial status
The first patient was randomized on 13 January
2014 and the recruitment is expected to complete by
February 2016. The study recruitment is continuing
as planned.
Additional file
Additional file 1: Model informed consent form. (PDF 237 kb)
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